Clement CHEW

Barrington James亚太办公室副总监

Clement Chew (周晋锋） Associate Director Life Sciences Recruitment Clement serves as Associate Director for the APAC Regional Office at Barrington James, a global leading life sciences recruitment firm. He has been recruiting within the life sciences industry since 2009 and has a successful history supporting organizations recruit the best talent in the market as well as helping candidates take their career to the next level. The team at Barrington James focuses on mid to senior level recruitment for the APAC region in functional areas such as medical affairs, clinical development, regulatory affairs, clinical research, quality, market access, R&D, HEOR and commercial (sales and marketing).

吴舟艳

默沙东研发（中国）有限公司人力资源部副总监，HR商务合伙人

Amy Wu serves as HR Leader to support MSD China R&D since 2012 when the R&D center was newly set up. She sits in MSD R&D leadership team and China HR Leadership team . Amy is playing a very important role to design and execute the MSD China R&D Talent Strategy Roadmap in the past years and with proven successful track record to support business development and success. She was recognized as a great business partner to develop organization capability and a professional HR consultant to help business going through various challenging experience. Amy is with 13 years of HR consulting and practice with Fortune Top 500 company. Before MSD China R&D , Amy was HRBP of Adobe Systems supporting Adobe Greater China(China mainland, HK, TW). Amy Wu received her M.S degree in Beihang University, majored in English Linguistics.

张明强 博士

安进公司全球研发副总裁

张明强 博士 全球研发副总裁 美国安进公司 张明强博士现任美国安进公司全球研发副总裁、全球转化医学领导团队成员、亚洲研发中心负责人、安进生物医药研发（上海）有限公司总经理、法人代表。张博士同时兼任中国外商投资企业协会药品研制和开发行业委员会(RDPAC)研发委员会主席、中国药学会药物化学专业委员会副主任委员、中欧生物医药委员会副主席、以及若干政府和产业机构生物医药产业顾问。张博士从事新药研发20多年，在中枢神经、肿瘤、炎症和病毒等疾病领域的新药研发中，多有建树。他领导开发和作为第一发明人的全球首创肌松药拮抗剂布瑞亭（默沙东，舒更葡糖钠注射液）已在全球60多个国家成功上市, 年销售约5亿美元。 张博士已发表/发明100多篇论文/专利。他是英国皇家化学会院士，全英华人生命科学院院士并担任欧洲药物化学联合会学术顾问委员会委员，【MedChemComm】、【Current Drug Discovery】、【Chinese J Med Chem】、【BAO J Pharm Sci】等学术杂志编委。他是2007年英国皇家化学会“莫肯-坎贝尔”纪念大奖得主，也是2008年苏格兰“尼科舍斯”生命科学创新奖获得者。2016年Bridion荣获有“生物医药界诺贝尔奖”的美国盖伦奖(Prix Galien USA) “最佳创新药物”提名。在加入安进公司之前，张博士曾任美国默沙东公司全球研发副总裁、亚太区研发总裁，并担任“默沙东研发（中国）有限公司”创始总经理、法人代表。张博士还创建过研发型企业，其中致力于抗病毒新药研发的ViroChem公司于2009年以3亿8千万美元为美国Vertex公司所兼并。

杨建新 医学博士

基石药业临床开发高级副总裁、首席医学官

杨建新 Chief Medical Officer Senior Vice President，Clinical Development National “Thousand Talents” Expert MD, PhD in Molecular Genetics Dr. Jason Yang joined CStone Pharmaceuticals in 2016, as its Chief Medical Officer (CMO). He has over 25 years of global experience in biomedical research and clinical development of oncology drugs. Prior to joining CStone, Dr. Jason Yang served as the Senior Vice President and Head of Clinical Development at BeiGene since 2014. He and his team generated key safety and proof of concept efficacy data that supported BeiGene’s two successful financing rounds in 2014 and 2015, the IPO and a follow-on offering in the US NASDAQ market in 2016. Prior to joining BeiGene, Dr. Yang served as Oncology Medical Director at Covance, Senior Principal Scientist in oncology translational biomarkers at Pfizer, and Research Scientist in cancer genomics at Tularik/Amgen. Throughout his career, Dr. Yang has made significant contributions to the successful development of several anticancer drugs. He is also the author of over 30 publications and the inventor of 9 patents. In 2015, he is honored as a “Distinguished Expert” by the China’s national “1000 Talents Program” and the Beijing “Haiju Program.” Dr. Yang was trained as a physician at Hubei Medical College and Nanjing Medical University. He then received his PhD training with Nobel Laureates Drs. Mike Brown and Joseph Goldstein at the University of Texas Southwestern Medical Center at Dallas. He completed his postdoctoral training with Dr. Stuart Schreiber at Harvard University.

焦庆安

强生（中国）投资有限公司全球临床研究运营部高级总监

焦庆安 医师 / Qinan JIAO, MD, MSc 西安杨森制药有限公司全球临床研究运营部高级总监 Sr. Director, Global Clinical Research Operation, Xian Janssen Pharmaceutical Co.,Ltd. 焦庆安医师目前是杨森（中国）研发中心全球临床研究运营部高级总监，负责中国临床研究运营部的管理。 他在药物开发和临床研究领域拥有20多年的丰富的项目管理和人员管理经验。 在加入杨森公司之前，焦庆安医师在罗氏、赛诺菲、MDS Pharma Services及辉瑞公司的中国或亚太研发中心就任不同的管理或高级管理职位，管理了中国或亚太区的不同规模的临床研究团队和多项国际多中心临床试验。 他于1986年获得临床医学本科学位，1989年获得医学免疫学硕士学位。 焦庆安医师曾是DIA中国区临时顾问委员会成员，并经常被邀请在国内外药物研发的大会或研讨会上做关于药物临床研究方面的专题演讲或参与嘉宾讨论。 Dr. QingAn JIAO is currently Senior Director, Head of Global Clinical Operations (GCO) China, at Janssen (China) Research & Development Center, a Division of Johnson & Johnson (China) Investment Ltd. He has over 20 years of experience in drug development and clinical research, and is very experienced in managing clinical trials and clinical operations team in China and in Asia Pacific. Prior to joining Janssen, he was taking different management or senior management roles in China or Asia Pacific R&D Center at Roche, Sanofi, MDS Pharma Services and Pfizer, managing medium or large sized clinical operations team, with extensive experience in the management of multinational clinical trials in China and in Asia Pacific. He received his Medical degree in 1986 and Master degree in Medical Immunology in 1989. He has spoken at various international and national conferences and seminars on topics of clinical research and R&D activities, and was one of the members of the DIA Provisional Advisory Council of China (pACC).